Clinical Trial: 68Ga-NYM215 in NENs

U.S., Sept. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07835906) titled '68Ga-NYM215 in NENs' on Sept. 17.

Brief Summary: This prospective study will evaluate the safety, biodistribution, dosimetry, and imaging performance of 68Ga-NYM215 PET/CT in patients with neuroendocrine neoplasms. An head-to-head comparison with 68Ga-DOTATATE PET/CT will assess the diagnostic performance of 68Ga-NYM215 PET/CT at both the patient and lesion levels.

Study Start Date: Sept. 10

Study Type: INTERVENTIONAL

Condition: Neuroendocrine Neoplasms

Intervention: DIAGNOSTIC_TEST: 68Ga-NYM215 PET/CT

40 patients will be enrolled in this arm. Each patients will be injected with approximately 3mCi 68Ga-NYM215. The first 8 pa...